Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Immunic earned the exclusive rights to develop a group of innovative disease-modifying therapies, now renamed IMU-856, for inflammatory bowel disease (IBD). IMU-856, originally developed by Daiichi Sankyo, is an oral ... Read more
Antibiotics can disrupt immune cells residing in the gut, triggering the rise of pro-inflammatory cells and reducing healthy bacteria — two steps key in the development of inflammatory bowel ... Read more
Abivax‘s small, anti-inflammatory molecule ABX464 significantly increased clinical remission and mucosal healing over placebo in patients with moderate to severe active ulcerative colitis resistant to other therapies, top-line results from ... Read more
The European Commission has approved Pfizer‘s Xeljanz (tofacitinib) for the treatment of adults with moderate to severe active ulcerative colitis (UC) who have failed to fully respond to other therapies. ... Read more
Aerpio Pharmaceuticals announced a licensing agreement with Gossamer Bio to develop and commercialize Aerpio’s investigative therapy AKB-4924 as a treatment for inflammatory bowel disease (IBD). AKB-4924 (to be changed to GB004) is a hypoxia-inducible factor-1 ... Read more